Zohreh Mohammadi Zaniani, Mehrdad Zeinalian, Mohammad Amin Tabatabaiefar
{"title":"家族性非髓样甲状腺癌:伊朗患者的病例系列与病例系列的荟萃回顾。","authors":"Zohreh Mohammadi Zaniani, Mehrdad Zeinalian, Mohammad Amin Tabatabaiefar","doi":"10.1093/labmed/lmad098","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Nonmedullary thyroid cancer (NMTC) comprises approximately 90% of all thyroid cancers, and about 3% to 9% of NMTC cases have a familial origin. Familial NMTC (FNMTC) in the absence of a documented familial cancer syndrome such as Cowden syndrome is characterized by the occurrence of thyroid cancer of follicular cell origin in 2 or more first-degree relatives.</p><p><strong>Methods: </strong>Whole-exome sequencing (WES) was used to identify pathogenic genetic variants in 2 Persian families with FNMTC. The purpose of this work is to assess the pathogenic status of these variants as well as the cosegregation status of the variants observed in the examined families.</p><p><strong>Results: </strong>By analyzing WES data in the first family, SRGAP1: NM_020762: exon16: c.C1849T was identified as a pathogenic variant. This variant was confirmed by Sanger sequencing. In the second family, the variant FOXE1: NM_004473: exon1: c.531_532insCGCGA was identified but was not confirmed by Sanger sequencing.</p><p><strong>Conclusion: </strong>Based on the data, SRGAP1 can be a potential candidate gene for susceptibility to FNMTC in the first family. However, additional analyses like whole genome sequencing and copy number variations are required to ascertain the disease status in second family.</p>","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":" ","pages":"506-516"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Familial nonmedullary thyroid cancer: a case series in Iranian patients with a meta-review of case series.\",\"authors\":\"Zohreh Mohammadi Zaniani, Mehrdad Zeinalian, Mohammad Amin Tabatabaiefar\",\"doi\":\"10.1093/labmed/lmad098\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Nonmedullary thyroid cancer (NMTC) comprises approximately 90% of all thyroid cancers, and about 3% to 9% of NMTC cases have a familial origin. Familial NMTC (FNMTC) in the absence of a documented familial cancer syndrome such as Cowden syndrome is characterized by the occurrence of thyroid cancer of follicular cell origin in 2 or more first-degree relatives.</p><p><strong>Methods: </strong>Whole-exome sequencing (WES) was used to identify pathogenic genetic variants in 2 Persian families with FNMTC. The purpose of this work is to assess the pathogenic status of these variants as well as the cosegregation status of the variants observed in the examined families.</p><p><strong>Results: </strong>By analyzing WES data in the first family, SRGAP1: NM_020762: exon16: c.C1849T was identified as a pathogenic variant. This variant was confirmed by Sanger sequencing. In the second family, the variant FOXE1: NM_004473: exon1: c.531_532insCGCGA was identified but was not confirmed by Sanger sequencing.</p><p><strong>Conclusion: </strong>Based on the data, SRGAP1 can be a potential candidate gene for susceptibility to FNMTC in the first family. However, additional analyses like whole genome sequencing and copy number variations are required to ascertain the disease status in second family.</p>\",\"PeriodicalId\":94124,\"journal\":{\"name\":\"Laboratory medicine\",\"volume\":\" \",\"pages\":\"506-516\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Laboratory medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/labmed/lmad098\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/labmed/lmad098","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:非髓样甲状腺癌(NMTC)约占所有甲状腺癌的90%,其中约3%至9%的NMTC病例具有家族起源。家族性NMTC (FNMTC)在没有家族性癌症综合征(如考登综合征)的情况下,其特征是在2个或更多一级亲属中发生起源于滤泡细胞的甲状腺癌。方法:采用全外显子组测序(WES)对2个波斯FNMTC家族进行致病基因变异鉴定。这项工作的目的是评估这些变异的致病状态,以及在检查的家庭中观察到的变异的共分离状态。结果:通过分析第一家族的WES数据,鉴定出SRGAP1: NM_020762: exon16: c.C1849T为致病变异。Sanger测序证实了该变异。在第二个家族中,发现了变异FOXE1: NM_004473: exon1: c. 531_532insccgga,但未通过Sanger测序证实。结论:SRGAP1可能是第一家族FNMTC易感性的潜在候选基因。然而,需要全基因组测序和拷贝数变异等额外分析来确定第二家庭的疾病状况。
Familial nonmedullary thyroid cancer: a case series in Iranian patients with a meta-review of case series.
Background: Nonmedullary thyroid cancer (NMTC) comprises approximately 90% of all thyroid cancers, and about 3% to 9% of NMTC cases have a familial origin. Familial NMTC (FNMTC) in the absence of a documented familial cancer syndrome such as Cowden syndrome is characterized by the occurrence of thyroid cancer of follicular cell origin in 2 or more first-degree relatives.
Methods: Whole-exome sequencing (WES) was used to identify pathogenic genetic variants in 2 Persian families with FNMTC. The purpose of this work is to assess the pathogenic status of these variants as well as the cosegregation status of the variants observed in the examined families.
Results: By analyzing WES data in the first family, SRGAP1: NM_020762: exon16: c.C1849T was identified as a pathogenic variant. This variant was confirmed by Sanger sequencing. In the second family, the variant FOXE1: NM_004473: exon1: c.531_532insCGCGA was identified but was not confirmed by Sanger sequencing.
Conclusion: Based on the data, SRGAP1 can be a potential candidate gene for susceptibility to FNMTC in the first family. However, additional analyses like whole genome sequencing and copy number variations are required to ascertain the disease status in second family.